Answers are grounded in this paper and cite their sources.
Twenty-five years have elapsed since the initial publication detailing the outpatient use of intravenous antimicrobials [1]. Since that time, numerous articles have appeared in the medical literature documenting the validity, safety, cost-effectiveness, and societal benefits of and patient satisfaction with the use of outpatient intravenous therapy for a variety of illnesses. It is estimated that >250,000 Americans are treated annually in this manner, generating almost $2 billion in revenue. Although many of the patients who were first treated with outpatient intravenous antimicrobial therapy (OPAT) had osteomyelitis, a wide variety of other conditions, including cellulitis and soft-tissue infections, respiratory and sinus infections, visceral abscesses, complicated urinary tract infections, pelvic inflammatory disease, febrile neutropenia, primary bacteremia, Lyme disease, and fungal and viral infections, have all been safely treated out of the hospital setting. Serious and potentially life-threatening infections such as infective endocarditis have recently also been shown to be effectively treated with OPAT, as long as the patients are carefully selected and closely monitored. Several factors have contributed to the success of outpatient therapy, including potent anti-microbials with prolonged half-lives, allowing for infrequent administrations, newer intravenous access devices, and medication delivery systems that carefully control the time and rate of infusions [2]. Economic demands by third-party payers and managed care providers have also been an impetus for early hospital discharge. The net result has been an increasing number of patients who are now treated with parenteral anti-microbials out of the hospital setting [3]. Criteria have been developed for selection of patients and for monitoring during OPAT. Recently, the Infectious Diseases Society of America has published guidelines for community-based parenteral anti-infective therapy [4]. The Joint Commission on Accreditation of Healthcare Organizations (JCAHO) has developed indications for outpatient intravenous therapy, emphasizing outcomes, clinical endpoints, complications, quality of life, and patient satisfaction. JCAHO patient-selection criteria for outpatient therapy include a diagnosis with a defined and predictable prognosis; stable vital signs, including a temperature that is approaching normal; an infection that is stabilized and nonprogressive; and complications that are easily treatable. Other organizations, including the Outpatient Intravenous Therapy Association, have been instrumental in educating physicians, nurses, and pharmacists in the technical and administrative aspects of outpatient therapy, and a registry has been established to track clinical outcomes. There has been general agreement that a team approach involving physicians, nurses, pharmacists, and administrators is necessary to provide optimal care to patients receiving OPAT, whether they are treated in a clinic, infusion center, or doctor's office [5]. Although several studies have shown the efficacy and safety of OPAT, there have been few prospective studies comparing the risks of outpatient versus inpatient therapy. Accordingly, it is reasonable to carefully evaluate specific infections to determine the feasibility of outpatient therapy. CNS infections, for example, have been classically treated in the hospital for prolonged periods of time. Many of these infections can be quite serious; the mortality associated with bacterial meningitis, for instance, may be as high as 25% [6]. The pediatric literature includes several references that document the safety and excellent results of OPAT for children with meningitis initially treated in the hospital. Criteria for outpatient therapy include being afebrile for 24–48 h, having no neurological complications or evidence of the syndrome of inappropriate secretion of antidiuretic hormone, and having a good clinical response to therapy [7–9]. Continuing treatment with OPAT for children who meet these criteria is now well accepted. Aside from anecdotal reports in the internal medicine literature, there have been no critical evaluations of adults with CNS infections who have been treated with parenteral anti-biotics as outpatients. In this issue, Tice and colleagues have retrospectively analyzed their experience with 68 patients who had a variety of CNS infections, including bacterial meningitis, brain and epidural abscesses, shunt infections, and encephalitis. At the time of discharge from the hospital, the patients had essentially met the same criteria as previously described in the pediatric literature. Outpatient therapy ranged from 2 to 89 days, with a mean of 18 days. The patients were treated predom-inantly with ceftriaxone, but many other antimicrobials were also used. Complications included seizures (in 2 patients) that were controlled with medication, a number of not-unexpected drug reactions, and rehospitalization of 11 patients for various reasons. There appeared to be no more adverse effects among those individuals treated out of the hospital setting than would be expected if hospitalization had been continued. The final result was that all patients were cured and no deaths occurred during therapy. Although a detailed financial analysis was not performed, the estimated cost savings of treating these patients on an outpatient basis was significant. Can these investigators' experience be generalized? Why were the results so positive, and can we assume that other programs will have similar outcomes? No doubt, part of the success in the series of Tice et al. is related to the team approach and experience of the group. Patients were appropriately selected and carefully monitored during therapy. Seizure activity was anticipated and prophylactic medications were considered in advance. The patients were followed closely by an attending physician, and necessary laboratory tests were performed at regular intervals. Venous access sites were scrupulously maintained. Potential complications were prevented as much as possible. With the advent of managed care and contracted home care agencies, the team approach may be jeopardized in the future. Physicians, although medicolegally responsible for their patients, could be put in the awkward position of signing orders and not being able to follow their patients closely. Although guidelines for drug selection, dosage, and duration of anti-microbial therapy have been suggested [10], nothing can replace the direct hands-on observations of an experienced physician. If we expect to achieve results similar to those achieved by Tice et al., we cannot jeopardize patient care by allowing contracted providers to substitute for the direct involvement of physicians. The decision to discharge patients from the hospital with a specific diagnosis in order to initiate OPAT should be based on objective criteria and not be the result of pressures from third-party payers. Physicians with experience in OPAT must continue to take a leadership role in the outpatient management of their patients.
No takes yet. Share an insight, caveat, or question.
Donald M. Poretz (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: